

# Gabriel N Hortobagyi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4728720/publications.pdf>

Version: 2024-02-01

331  
papers

46,211  
citations

2975

93  
h-index

2033

205  
g-index

339  
all docs

339  
docs citations

339  
times ranked

36447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529.	27.0	2,474
2	Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1275-1281.	1.6	2,387
3	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. <i>Cancer Cell</i> , 2004, 6, 117-127.	16.8	1,693
4	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	27.0	1,390
5	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 55-65.	10.7	1,252
6	Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4414-4422.	1.6	1,243
7	Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 1999, 17, 460-460.	1.6	1,199
8	Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3676-3685.	1.6	1,076
9	Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1420-1430.	1.6	1,012
10	The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. <i>Oncologist</i> , 2009, 14, 320-368.	3.7	986
11	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
12	Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. <i>Cancer Research</i> , 2009, 69, 4116-4124.	0.9	768
13	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	7.0	710
14	Treatment of Breast Cancer. <i>New England Journal of Medicine</i> , 1998, 339, 974-984.	27.0	695
15	Prognosis of Women With Metastatic Breast Cancer by <i>HER2</i> Status and Trastuzumab Treatment: An Institutional-Based Review. <i>Journal of Clinical Oncology</i> , 2010, 28, 92-98.	1.6	666
16	Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 290-303.	329.8	649
17	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016, 7, 12632.	12.8	648
18	Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 1999, 17, 846-846.	1.6	597

#	ARTICLE	IF	CITATIONS
19	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. <i>Clinical Cancer Research</i> , 2013, 19, 5533-5540.	7.0	597
20	Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. , 2000, 88, 1082-1090.		592
21	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. <i>Nature Cell Biology</i> , 2008, 10, 138-148.	10.3	590
22	IKK $\beta$ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway. <i>Cell</i> , 2007, 130, 440-455.	28.9	585
23	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014, 32, 3483-3489.	1.6	543
24	Deubiquitination and Stabilization of PD-L1 by CSN5. <i>Cancer Cell</i> , 2016, 30, 925-939.	16.8	538
25	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. <i>Journal of Clinical Oncology</i> , 2017, 35, 1049-1060.	1.6	478
26	Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. <i>Cancer</i> , 1988, 62, 2507-2516.	4.1	472
27	Is breast cancer survival improving?. <i>Cancer</i> , 2004, 100, 44-52.	4.1	469
28	The Global Breast Cancer Burden: Variations in Epidemiology and Survival. <i>Clinical Breast Cancer</i> , 2005, 6, 391-401.	2.4	445
29	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. <i>Advances in Therapy</i> , 2013, 30, 870-884.	2.9	430
30	Management of Breast Cancer During Pregnancy Using a Standardized Protocol. <i>Journal of Clinical Oncology</i> , 1999, 17, 855-855.	1.6	400
31	Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1310.	7.1	395
32	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. <i>Cancer Cell</i> , 2018, 33, 187-201.e10.	16.8	381
33	Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 9304-9311.	1.6	366
34	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	27.0	363
35	Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1783-1785.	1.5	359
36	Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2005, 23, 41-48.	1.6	352

#	ARTICLE	IF	CITATIONS
37	Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 435-444.	27.0	352
38	Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. <i>Cancer</i> , 2006, 107, 1219-1226.	4.1	342
39	Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. <i>Journal of Clinical Oncology</i> , 2006, 24, 4107-4115.	1.6	336
40	The natural history of breast cancer patients with brain metastases. <i>Cancer</i> , 1979, 44, 1913-1918.	4.1	279
41	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , 2019, 20, 835-851.	14.5	277
42	Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4952-4960.	1.6	258
43	Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome. <i>Journal of Clinical Oncology</i> , 2007, 25, 2650-2655.	1.6	253
44	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 321-329.	2.3	242
45	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	16.8	240
46	Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. <i>Cancer</i> , 1992, 69, 2849-2852.	4.1	238
47	Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. <i>Oncologist</i> , 2008, 13, 477-493.	3.7	235
48	Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 3412-3417.	1.6	234
49	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	27.0	220
50	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. <i>JAMA Oncology</i> , 2015, 1, 931.	7.1	216
51	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2â€“Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	1.6	210
52	Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 3126-3132.	1.6	207
53	PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1093-1101.	4.1	204
54	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 264-272.	6.3	203

#	ARTICLE	IF	CITATIONS
55	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	1.6	203
56	Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience. <i>Journal of Clinical Oncology</i> , 2001, 19, 628-633.	1.6	200
57	Inflammatory breast cancer (IBC) and patterns of recurrence. <i>Cancer</i> , 2007, 110, 1436-1444.	4.1	194
58	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. <i>Cancer Research</i> , 2016, 76, 1284-1296.	0.9	190
59	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. <i>Nature Medicine</i> , 2016, 22, 194-201.	30.7	189
60	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011, 13, R67.	5.0	188
61	Anthracycline Antibiotics in Cancer Therapy. <i>Drugs</i> , 1994, 47, 223-258.	10.9	170
62	Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. <i>Cancer</i> , 1991, 68, 549-557.	4.1	161
63	Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. <i>Journal of the National Cancer Institute</i> , 2000, 92, 225-233.	6.3	161
64	Circulating tumor cells in metastatic breast cancer. <i>Cancer</i> , 2008, 113, 2422-2430.	4.1	156
65	Female patients with breast carcinoma age 30 years and younger have a poor prognosis. <i>Cancer</i> , 2001, 92, 2523-2528.	4.1	154
66	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 203.	7.1	152
67	Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. <i>American Journal of Surgery</i> , 1998, 176, 502-509.	1.8	149
68	Molecular predictors of response to trastuzumab and lapatinib in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 98-107.	27.6	148
69	Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. <i>Cancer</i> , 2007, 110, 2640-2647.	4.1	147
70	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). <i>Journal of Clinical Oncology</i> , 2020, 38, 804-814.	1.6	142
71	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. <i>Clinical Breast Cancer</i> , 2007, 7, 34-42.	2.4	141
72	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	5.0	141

#	ARTICLE	IF	CITATIONS
73	Circulating Tumor Cells and [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3303-3311.	1.6	139
74	The Use of Alternate, Non- <sup>19</sup> Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 2294-2302.	1.6	137
75	TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	135
76	Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone. <i>JAMA Oncology</i> , 2017, 3, 906.	7.1	134
77	Predictors of Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1821-1828.	1.6	128
78	Update on the Management of Inflammatory Breast Cancer. <i>Oncologist</i> , 2003, 8, 141-148.	3.7	126
79	Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 392-398.	0.8	126
80	Oral bisphosphonates. <i>Cancer</i> , 2000, 88, 6-14.	4.1	124
81	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998, 16, 2087-2094.	5.9	122
82	Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. <i>Cancer</i> , 1986, 58, 2589-2593.	4.1	120
83	Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. <i>Cancer</i> , 1990, 65, 847-850.	4.1	120
84	Role of adjuvant chemotherapy in male breast cancer. <i>Cancer</i> , 1989, 64, 1583-1585.	4.1	118
85	Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. , 1999, 85, 104-111.		118
86	Multidisciplinary management of advanced primary and metastatic breast cancer. <i>Cancer</i> , 1994, 74, 416-423.	4.1	115
87	Doxorubicin-induced congestive heart failure in adults. <i>Cancer</i> , 1985, 56, 1361-1365.	4.1	114
88	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2 <sup>+</sup> advanced breast cancer: results from BOLERO-2. <i>British Journal of Cancer</i> , 2017, 116, 726-730.	6.4	112
89	Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. <i>Oncogene</i> , 1998, 16, 2855-2863.	5.9	108
90	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor <sup>+</sup> Positive Breast Cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013, 13, 421-432.e8.	2.4	104

#	ARTICLE	IF	CITATIONS
91	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 508.	7.1	103
92	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 54-63.	6.3	98
93	Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. <i>Cancer</i> , 1994, 73, 2157-2167.	4.1	97
94	Risks and Benefits of Taxanes in Breast and Ovarian Cancer. <i>Drug Safety</i> , 2000, 23, 401-428.	3.2	97
95	Future directions of bone-targeted therapy for metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 641-651.	27.6	97
96	Chemotherapy: What Progress in the Last 5 Years?. <i>Journal of Clinical Oncology</i> , 2005, 23, 1760-1775.	1.6	96
97	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1226-1234.	27.0	95
98	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 929.	7.1	94
99	Treatment for meningeal carcinomatosis in breast cancer. <i>Cancer</i> , 1982, 50, 219-222.	4.1	93
100	Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System. <i>Journal of Clinical Oncology</i> , 2011, 29, 4654-4661.	1.6	92
101	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e83113.	2.5	91
102	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2 <sup>+</sup> advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 127-134.	2.5	90
103	Leptomeningeal carcinomatosis in patients with breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 85-94.	4.4	90
104	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3214-3223.	1.6	89
105	SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 58-64.	1.6	89
106	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013, 105, 654-663.	6.3	88
107	Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 1425-1425.	1.6	86
108	Locally Advanced Breast Cancer. <i>Oncologist</i> , 1996, 1, 8-17.	3.7	85



#	ARTICLE	IF	CITATIONS
109	Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s. <i>Cancer</i> , 1985, 55, 341-346.	4.1	84
110	New and Important Changes in the TNM Staging System for Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 457-467.	3.8	83
111	Developments in chemotherapy of breast cancer. <i>Cancer</i> , 2000, 88, 3073-3079.	4.1	82
112	The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. <i>Oncogene</i> , 1997, 14, 561-568.	5.9	81
113	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013, 119, 1908-1915.	4.1	81
114	The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 262-268.	3.3	81
115	Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. <i>Seminars in Oncology</i> , 2001, 28, 43-47.	2.2	76
116	Outcomes of children exposed in utero to chemotherapy for breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 500.	5.0	75
117	Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared With Nonpregnant Patients With Breast Cancer. <i>Oncologist</i> , 2013, 18, 369-376.	3.7	74
118	Everolimus plus exemestane as first-line therapy in HR+, HER2 <sup>+</sup> advanced breast cancer in BOLERO-2. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 459-467.	2.5	74
119	Inflammatory breast cancer: a proposed conceptual shift in the UICC/AJCC TNM staging system. <i>Lancet Oncology</i> , 2017, 18, e228-e232.	10.7	74
120	Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial. <i>Cancer</i> , 1984, 53, 384-389.	4.1	73
121	A Shortage of Oncologists? The American Society of Clinical Oncology Workforce Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 1468-1469.	1.6	73
122	Management of inflammatory carcinoma of breast with combined modality approach—an update. <i>Cancer</i> , 1981, 47, 2537-2542.	4.1	72
123	Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 673-680.	1.5	72
124	Ten-Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989, 12, 123-128.	1.3	71
125	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. <i>Stem Cells Translational Medicine</i> , 2014, 3, 849-856.	3.3	69
126	Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. <i>Cancer</i> , 1981, 47, 2798-2802.	4.1	67



#	ARTICLE	IF	CITATIONS
127	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. <i>Clinical Breast Cancer</i> , 2007, 7, 471-9.	2.4	67
128	Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. <i>Cancer</i> , 1978, 41, 1064-1075.	4.1	65
129	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 409-418.	2.5	65
130	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. <i>Cancer Research</i> , 2016, 76, 1451-1462.	0.9	65
131	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5114.	12.8	64
132	Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. <i>Cancer</i> , 1992, 69, 448-452.	4.1	63
133	Current challenges of metastatic breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 495-514.	5.9	63
134	The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. <i>Cancer</i> , 1993, 71, 3680-3684.	4.1	62
135	Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCC. <i>Cancer</i> , 1979, 43, 1225-1233.	4.1	61
136	Angiosarcoma arising in an irradiated breast. A case report and review of the literature. <i>Cancer</i> , 1989, 64, 2214-2216.	4.1	61
137	Definition of PKC- $\zeta$ , CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4822-4835.	0.9	61
138	Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. <i>Ca-A Cancer Journal for Clinicians</i> , 1995, 45, 199-226.	329.8	59
139	<i>TP53</i> mutation-correlated genes predict the risk of tumor relapse and identify <i>MPS1</i> as a potential therapeutic kinase in <i>TP53</i> -mutated breast cancers. <i>Molecular Oncology</i> , 2014, 8, 508-519.	4.6	59
140	Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 2314-2320.	2.8	58
141	Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?. <i>Cancer</i> , 1990, 65, 394-399.	4.1	57
142	Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. <i>Pathology and Oncology Research</i> , 2001, 7, 171-177.	1.9	56
143	Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2. <i>Neoplasia</i> , 2015, 17, 279-288.	5.3	56
144	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013, 49, 2621-2632.	2.8	53

#	ARTICLE	IF	CITATIONS
145	Molecular targets for treatment of inflammatory breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 387-394.	27.6	52
146	Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 471-478.	2.3	51
147	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	7.1	51
148	Breast conservation therapy as a treatment option for the elderly. <i>Cancer</i> , 2001, 92, 1092-1100.	4.1	50
149	Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA509-LBA509.	1.6	49
150	Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). <i>Journal of Surgical Oncology</i> , 1979, 12, 27-40.	1.7	48
151	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707.	6.3	48
152	Five-day continuous-infusion vinblastine in the treatment of breast cancer. <i>Cancer</i> , 1985, 56, 225-229.	4.1	47
153	5-fluorouracil rechallenge by protracted infusion in refractory breast cancer. <i>Cancer</i> , 1989, 64, 793-797.	4.1	46
154	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 745-753.	2.5	46
155	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2991-3002.	7.0	46
156	Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. <i>Oncologist</i> , 2018, 23, 1282-1288.	3.7	46
157	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1300-1309.	3.7	46
158	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. <i>Clinical Cancer Research</i> , 2019, 25, 6089-6097.	7.0	46
159	Locally advanced breast cancer. <i>Cancer</i> , 2008, 113, 2315-2324.	4.1	45
160	Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1985, 5, 321-326.	2.5	44
161	A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. <i>Cancer</i> , 1985, 55, 337-340.	4.1	44
162	Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1569-1576.	2.8	44

#	ARTICLE	IF	CITATIONS
163	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 35656-35668.	1.8	44
164	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. <i>Cancer</i> , 1998, 82, 965-969.	4.1	43
165	Effect of Age and Race On Quality of Life in Young Breast Cancer Survivors. <i>Clinical Breast Cancer</i> , 2014, 14, e21-e31.	2.4	42
166	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	42
167	The prognostic significance of sialyl-tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. , 1997, 80, 2240-2249.		41
168	Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. <i>Breast Cancer Research</i> , 2018, 20, 123.	5.0	41
169	Characterization of bone only metastasis patients with respect to tumor subtypes. <i>Npj Breast Cancer</i> , 2018, 4, 2.	5.2	40
170	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€™Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€™Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	1.6	40
171	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 67904-67917.	1.8	40
172	Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview. <i>Journal of the National Cancer Institute Monographs</i> , 2001, 2001, 72-79.	2.1	39
173	Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2000, 7, 656-664.	1.5	38
174	Inflammatory Breast Carcinoma: The Sphinx of Breast Cancer Research. <i>Journal of Clinical Oncology</i> , 2004, 22, 381-383.	1.6	38
175	Staging of Breast Cancer in the Neoadjuvant Setting. <i>Cancer Research</i> , 2008, 68, 6477-6481.	0.9	38
176	Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 253-264.	2.5	38
177	Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 382-386.	2.3	36
178	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 155-164.	2.5	36
179	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 2.	5.0	36
180	Novel approaches to the management of bone metastases in patients with breast cancer. <i>Seminars in Oncology</i> , 2002, 29, 134-144.	2.2	36

#	ARTICLE	IF	CITATIONS
181	Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. <i>Journal of Surgical Oncology</i> , 1979, 11, 325-332.	1.7	35
182	Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. , 2000, 88, 2054-2060.		35
183	Functional consequence of the<i>MET-T</i>1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015, 6, 2604-2614.	1.8	34
184	Combined chemoimmunotherapy for advanced breast cancer.A comparison of BCG and levamisole. <i>Cancer</i> , 1979, 43, 1112-1122.	4.1	33
185	Ductal carcinoma-in-situ of the breast: Fine-needle aspiration cytology of 12 cases. <i>Diagnostic Cytopathology</i> , 1989, 5, 371-377.	1.0	33
186	Opportunities and challenges in the development of targeted therapies. <i>Seminars in Oncology</i> , 2004, 31, 21-27.	2.2	33
187	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. <i>Clinical Breast Cancer</i> , 2015, 15, 153-160.	2.4	33
188	Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy. , 1997, 79, 1150-1157.		32
189	Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. <i>Breast Journal</i> , 2010, 16, 327-330.	1.0	32
190	Phase I trail of droloxifene in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 313-316.	2.3	31
191	Primary Tumor Response to Induction Chemotherapy as a Predictor of Histological Status of Axillary Nodes in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 1999, 6, 762-767.	1.5	31
192	Supplement use during an intergroup clinical trial for breast cancer (S0221). <i>Breast Cancer Research and Treatment</i> , 2013, 137, 903-913.	2.5	31
193	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12780-12785.	7.1	31
194	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 57-67.	2.5	31
195	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1197.	2.8	30
196	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5365-5375.	7.0	29
197	Gene Signatureâ€“Guided Dasatinib Therapy in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5265-5271.	7.0	28
198	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019, 37, 345-351.	2.6	28

#	ARTICLE	IF	CITATIONS
199	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 749-757.	3.7	28
200	Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 1009-20.	0.0	28
201	Response of metastatic breast cancer to tamoxifen withdrawal: Report of a case. <i>Journal of Surgical Oncology</i> , 1983, 22, 45-46.	1.7	27
202	The natural history of breast carcinoma in patients with $\geq 10$ metastatic axillary lymph nodes before and after the advent of adjuvant therapy. <i>Cancer</i> , 2005, 104, 229-235.	4.1	27
203	Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3N0M0 Breast Cancer. <i>Annals of Surgical Oncology</i> , 2000, 7, 435-440.	1.5	26
204	Canalicular Stenosis as the Underlying Mechanism for Epiphora in Patients Receiving Weekly Docetaxel. <i>Oncologist</i> , 2001, 6, 551-552.	3.7	26
205	Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. <i>Cancer</i> , 2006, 106, 2327-2336.	4.1	26
206	Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. <i>Cancer</i> , 1979, 44, 1955-1962.	4.1	25
207	Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. <i>Cancer</i> , 1988, 62, 2098-2104.	4.1	25
208	Present Status of Anthracyclines in the Adjuvant Treatment of Breast Cancer. <i>Drugs</i> , 1993, 45, 10-19.	10.9	24
209	Health-related quality of life and disease symptoms in postmenopausal women with HR <sup>+</sup> , HER2 <sup>-</sup> advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	1.9	24
210	Bone marrow metastases without cortical bone involvement in breast cancer patients. <i>Cancer</i> , 1979, 44, 196-198.	4.1	23
211	New Approaches to Breast Cancer Therapy. <i>Breast Cancer Research and Treatment</i> , 2003, 80, 1-2.	2.5	23
212	Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. <i>Cancer</i> , 1980, 46, 438-445.	4.1	22
213	Trioxifene mesylate in the treatment of advanced breast cancer. <i>Cancer</i> , 1986, 57, 40-43.	4.1	22
214	A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. <i>Cancer</i> , 1992, 69, 476-481.	4.1	22
215	The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy. <i>Cancer</i> , 1989, 63, 828-835.	4.1	21
216	Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. <i>Cancer</i> , 2000, 89, 2195-2201.	4.1	21

#	ARTICLE	IF	CITATIONS
217	Breast Cancer, BRCA Mutations, and Attitudes Regarding Pregnancy and Preimplantation Genetic Diagnosis. <i>Oncologist</i> , 2014, 19, 797-804.	3.7	21
218	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. , 1999, 86, 1251-1257.		20
219	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015, 6, 310-318.	2.5	20
220	Inflammatory breast cancer: early recognition and diagnosis is critical. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 392-396.	1.3	20
221	Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer. <i>Cancer</i> , 1979, 44, 398-405.	4.1	19
222	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016, 21, 21-27.	3.7	19
223	Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020, 9, 1025-1032.	2.8	19
224	The evolving role of bisphosphonates. <i>Seminars in Oncology</i> , 2001, 28, 284-290.	2.2	19
225	Moving into the future: Treatment of bone metastases and beyond. <i>Cancer Treatment Reviews</i> , 2005, 31, 9-18.	7.7	18
226	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 325-331.	2.4	18
227	Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	6.0	18
228	Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. <i>Cancer</i> , 2004, 101, 913-917.	4.1	17
229	Toward Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside. <i>Oncologist</i> , 2012, 17, 577-584.	3.7	17
230	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). <i>Supportive Care in Cancer</i> , 2021, 29, 2509-2517.	2.2	17
231	Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. <i>Oncologist</i> , 1998, 3, 300-313.	3.7	17
232	Adriamycin and 1-(2-Chlorethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in the treatment of metastatic breast cancer. <i>Cancer</i> , 1978, 41, 1235-1239.	4.1	16
233	Paclitaxel-Induced Pancreatitis: A Case Report. <i>Journal of the National Cancer Institute</i> , 1997, 89, 91-93.	6.3	16
234	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 67-77.	2.5	16

#	ARTICLE	IF	CITATIONS
235	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 299-306.	2.6	16
236	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. <i>Journal of Clinical Oncology</i> , 2015, 33, 503-503.	1.6	16
237	Spontaneous regression of breast carcinoma: Follow-up report and literature review. <i>Journal of Surgical Oncology</i> , 1982, 19, 22-24.	1.7	15
238	Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer a prospective, randomized trial. <i>Cancer</i> , 1987, 60, 2596-2604.	4.1	15
239	Two Good Choices to Prevent Breast Cancer: Great Taste, Less Filling. <i>Cancer Prevention Research</i> , 2010, 3, 681-685.	1.5	15
240	Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. <i>Oncologist</i> , 2014, 19, 909-914.	3.7	15
241	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2687-2699.	4.1	15
242	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 648-661.	1.4	15
243	Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. <i>Journal of Biological Chemistry</i> , 2022, 298, 101817.	3.4	15
244	Phase I study of liposomal annamycin. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 427-432.	2.3	14
245	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0152585.	2.5	14
246	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , 2017, 8, 70481-70495.	1.8	14
247	Tumor-associated fever in breast cancer. <i>Cancer</i> , 1984, 53, 1596-1599.	4.1	13
248	Sequential cyclic combined hormonal therapy for metastatic breast cancer. <i>Cancer</i> , 1989, 64, 1002-1006.	4.1	13
249	Complications associated with indwelling catheters. <i>Medical and Pediatric Oncology</i> , 1992, 20, 22-25.	1.0	13
250	Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>Breast Cancer Research and Treatment</i> , 1999, 54, 225-233.	2.5	13
251	The Status of Breast Cancer Management: Challenges and Opportunities. <i>Breast Cancer Research and Treatment</i> , 2002, 75, 61-65.	2.5	13
252	BRCAPRO 6.0 Model Validation in Male Patients Presenting for <i>BRCA</i> Testing. <i>Oncologist</i> , 2015, 20, 593-597.	3.7	13



#	ARTICLE	IF	CITATIONS
253	The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine. <i>Journal of Clinical Oncology</i> , 2016, 34, 76-82.	1.6	13
254	Ribociclib for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 288-289.	27.0	13
255	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR- $\beta$ . <i>Investigational New Drugs</i> , 2018, 36, 1103-1109.	2.6	13
256	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. <i>Clinical Breast Cancer</i> , 2019, 19, 268-277.e1.	2.4	13
257	Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. <i>Cancer</i> , 1987, 59, 1992-1999.	4.1	12
258	Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7388-7395.	7.0	12
259	Long-Term Complications Associated With Breast-Conservation Surgery and Radiotherapy. <i>Annals of Surgical Oncology</i> , 2002, 9, 543-549.	1.5	12
260	Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. <i>American Journal of Cancer Research</i> , 2019, 9, 608-618.	1.4	12
261	Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. <i>Breast Cancer Research and Treatment</i> , 1996, 39, 177-185.	2.5	11
262	Progress in endocrine therapy for breast carcinoma. , 1998, 83, 1-6.		11
263	Using Response to Primary Chemotherapy to Select Postoperative Therapy: Long-Term Results from a Prospective Phase II Trial in Locally Advanced Primary Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 516-521.	2.4	11
264	Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5- $\alpha$ -fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer. <i>Cancer</i> , 2010, 116, 1210-1217.	4.1	11
265	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018, 124, 2299-2305.	4.1	11
266	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. <i>Nature Communications</i> , 2021, 12, 2788.	12.8	11
267	Combination chemotherapy for breast cancer metastatic to bone marrow. <i>Cancer</i> , 1981, 48, 227-232.	4.1	10
268	Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. <i>Cancer</i> , 2001, 91, 664-671.	4.1	10
269	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 458-466.	2.4	10
270	Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 789-804.	2.1	10

#	ARTICLE	IF	CITATIONS
271	Correlation of molecular alterations with efficacy of everolimus in hormone-receptorâ€“positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, LBA509-LBA509.	1.6	10
272	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2878-2889.	7.0	10
273	A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. Cancer, 1985, 56, 1320-1324.	4.1	9
274	Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 1989, 13, 117-121.	2.5	9
275	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer, 2017, 8, 1045-1052.	2.5	9
276	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clinical Cancer Research, 2021, 27, 6115-6123.	7.0	9
277	Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. Breast Cancer Research and Treatment, 1985, 6, 237-240.	2.5	8
278	Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer, 1988, 62, 2105-2110.	4.1	8
279	A phase II study of CI-973 [SP-4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N,) Tj ETQq1 1 0.784314 rgB Pharmacology, 1996, 38, 289-291.	2.3	8
280	Gemcitabine in Combination with Vinorelbine for Treatment of Advanced Breast Cancer. Clinical Breast Cancer, 2002, 3, S34-S38.	2.4	8
281	Novel approaches to the management of bone metastases. Seminars in Oncology, 2003, 30, 161-166.	2.2	8
282	American Society of Clinical Oncologyâ€™s Global Oncology Leadership Task Force: Findings and Actions. Journal of Global Oncology, 2018, 4, 1-8.	0.5	8
283	New and important changes in breast cancer TNM: incorporation of biologic factors into staging. Expert Review of Anticancer Therapy, 2019, 19, 309-318.	2.4	8
284	Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer, 1979, 44, 32-34.	4.1	7
285	Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. Journal of Cellular Biochemistry, 1993, 53, 37-43.	2.6	7
286	Phase II Vinorelbine (Navelbine®) by Continuous Infusion in Patients with Metastatic Breast Cancer: Cumulative Toxicities Limit Dose Escalation. Cancer Investigation, 2001, 19, 459-466.	1.3	7
287	Expanding Criteria for Prognostic Stage IA in Hormone Receptorâ€“Positive Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1744-1750.	6.3	7
288	Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer, 1982, 49, 1767-1770.	4.1	6

#	ARTICLE	IF	CITATIONS
289	Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials. <i>Oncologist</i> , 2010, 15, 476-483.	3.7	6
290	Estrogen Receptor: A Paradigm for Targeted Therapy. <i>Cancer Research</i> , 2021, 81, 5396-5398.	0.9	6
291	Anastrozole (Arimidex®), a New Aromatase Inhibitor for Advanced Breast Cancer: Mechanism of Action and Role in Management. <i>Cancer Investigation</i> , 1998, 16, 385-390.	1.3	5
292	A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. <i>Cancer</i> , 2010, 116, 1440-1445.	4.1	5
293	Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. <i>Current Breast Cancer Reports</i> , 2018, 10, 296-306.	1.0	5
294	Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics. <i>Cells</i> , 2021, 10, 433.	4.1	5
295	Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. <i>Clinical Cancer Research</i> , 2021, 27, 5343-5352.	7.0	5
296	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. <i>Journal of Clinical Oncology</i> , 2013, 31, 561-561.	1.6	5
297	Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. <i>Cancer</i> , 1984, 53, 1836-1840.	4.1	4
298	A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 157-61.	2.3	4
299	Secondary drug resistance in breast cancer: Failure to reverse with oral nifedipine. , 1997, 73, 184-186.		4
300	Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999, 55, 1-8.	2.5	4
301	Future Directions in the Endocrine Therapy of Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 80, 37-39.	2.5	4
302	A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. <i>Cancer</i> , 2010, 116, NA-NA.	4.1	4
303	Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. <i>Oncologist</i> , 2019, 24, 178-184.	3.7	4
304	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. <i>Clinical Cancer Research</i> , 2022, 28, 611-617.	7.0	4
305	Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. <i>Cancer</i> , 1987, 60, 1724-1728.	4.1	3
306	New Antiestrogens in Breast Cancer: A Review. <i>Breast Journal</i> , 1998, 4, 213-229.	1.0	3

#	ARTICLE	IF	CITATIONS
307	John Mendelsohn: A visionary scientist, oncologist and leader. <i>Genes and Cancer</i> , 2019, 10, 109-118.	1.9	3
308	Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. <i>Journal of Surgical Oncology</i> , 1979, 12, 333-341.	1.7	2
309	Anthracycline-resistant breast cancer. <i>Breast Cancer</i> , 1997, 4, 221-227.	2.9	2
310	Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 86-91.	2.3	2
311	A time for creative collaboration. <i>Cancer</i> , 2008, 113, 2217-2220.	4.1	2
312	Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 701-705.	2.5	2
313	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. <i>Npj Breast Cancer</i> , 2020, 6, 11.	5.2	2
314	CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. <i>Oncotarget</i> , 2018, 9, 34193-34195.	1.8	2
315	Survival outcomes in HER2-positive invasive lobular breast carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 612-612.	1.6	2
316	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2 <sup>+</sup> breast cancer. <i>Cancer Research</i> , 2022, 82, GS2-01-GS2-01.	0.9	2
317	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022, 82, PD2-05-PD2-05.	0.9	2
318	Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. <i>Journal of Surgical Oncology</i> , 1984, 26, 205-207.	1.7	1
319	Analysis of the Antitumor Agent Bay i 7433 (Copovithane) in Plasma and Urine by High Performance Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1984, 7, 159-166.	1.0	1
320	Radiotherapy enhances the toxicity of aminoglutethimide. <i>Medical and Pediatric Oncology</i> , 1990, 18, 162-164.	1.0	1
321	Personalized medicine for breast cancer: moving forward and going back. <i>Personalized Medicine</i> , 2006, 3, 363-370.	1.5	1
322	Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer—Reply. <i>JAMA Oncology</i> , 2018, 4, 586.	7.1	1
323	Bernard Fisher: A Pioneer Moves On. <i>Oncologist</i> , 2020, 25, 89-90.	3.7	1
324	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. <i>Cancers</i> , 2020, 12, 3105.	3.7	1

#	ARTICLE	IF	CITATIONS
325	Female patients with breast carcinoma age 30 years and younger have a poor prognosis. , 2001, 92, 2523.		1
326	Targeted Radiotherapy to the Skeleton Using <sup>166</sup> Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. Blood, 2004, 104, 5239-5239.	1.4	1
327	Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 1994, 33, 313-316.	2.3	1
328	Fingerprinting Lymph Node Metastases. Annals of Surgical Oncology, 2008, 15, 1275-1276.	1.5	0
329	Integration of docetaxel into adjuvant breast cancer treatment regimens. Oncology, 2002, 16, 27-33.	0.5	0
330	Why my neighbor's health is important to me. Oncology, 2010, 24, 1238.	0.5	0
331	Reply to A. Pfob and C. Sidey-Gibbons. JCO Clinical Cancer Informatics, 2022, 6, e2100171.	2.1	0